Biotech Business - January 20, 2026
Affibody carries out fully guaranteed rights issue
The Board of Directors of the company has resolved to carry out a fully guaranteed rights issue of SEK 307 million.
Global report - January 14, 2026
AstraZeneca acquires Modella AI
AstraZeneca is acquiring its AI partner Modella AI to own and deploy multimodal AI foundation models in‑house across discovery and development.
New Market - January 12, 2026
Novo Nordisk’s Wegovy pill now broadly available across America
Wegovy pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.
Financing - January 12, 2026
EpiEndo completes a EUR 9 million convertible bond issue
The company has raised EUR 5 million of new funding from new and existing investors via a EUR 9 million convertible bond issuance.
Agreement - January 4, 2026
Orexo in agreement with Dexcel to divest US rights to Zubsolv
The company has signed an agreement with Dexcel Pharma USA, to divest the full rights to Zubsolv (buprenorphine/naloxone) sublingual tablet CIII, for the treatment of opioid use disorder, in the US.
Agreement - December 17, 2025
Camurus and Gubra enter agreement
Camurus and Gubra have entered into an exclusive collaboration and license agreement aimed at creating a long-acting therapeutic option for the treatment of hypoparathyroidism.
